Newly published discoveries have revealed possibilities for the treatment of cancer by targeting tumour-associated macrophages (TAMs) in the tumour microenvironment (TME). The founding scientists behind Edinburgh-based Macomics, Dr Luca Cassetta and Professor Jeff Pollard, detail the seminal discoveries in macrophage biology over the past 50 years in… Read More
Aura Biosciences has announced positive interim Phase II safety and efficacy data for belzupacap sarotalocan (bel-sar) as a first-line treatment for patients with early-stage choroidal melanoma with suprachoroidal administration. The results showed a statistically significant reduction in tumour growth rate compared to each patient’s documented growth rate… Read More
A new multi-year strategic partnership between M2GEN and Zephyr AI will leverage clinicogenomic data, bioinformatics, and artificial intelligence to accelerate drug discovery and expanded use cases for oncology treatments. In this partnership, M2GEN will license its real-world data set (RWD) to Zephyr AI, while Zephyr AI will… Read More
Listen to this article on the DDW Podcast: By Dr Shailendra Singh, founder and CEO of Cellomatics Biosciences. Cancer is a complex heterogenous multistep disease characterised by uncontrolled cell proliferation combined with a dysregulated immune response. The number of new cases recorded between 2016 and 2018 was… Read More
AI company Absci and St John’s Cancer Institute (SJCI) have entered a partnership to uncover breakthrough cancer therapies. The companies will use Absci’s Integrated Drug Creation platform, which combines generative AI models and proprietary wet-lab technologies, and SJCI’s cancer biospecimen repository and molecular database to identify new… Read More
Breast cancer retained its position as the most-studied disease area in clinical trials in 2022, despite a drop in activity, according to analysis from analytics company Phesi. The company’s global analysis of all clinical trials conducted in 2022 showed that Covid-19 came second. Three of… Read More
Listen to this article on the DDW Podcast: Why data from a Phase III clinical trial offers promise for patients with a deadly form of brain cancer. A Phase III clinical trial has produced promising results for a cancer vaccine targeting patients with a new or recurrent… Read More
The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation to AstraZeneca for Imfinzi (durvalumab) in combination with gemcitabine and cisplatin in Great Britain for use as a first-line treatment of adults with locally advanced, unresectable or metastatic biliary tract cancer (BTC).1 This authorisation by… Read More
Listen to this article on the DDW Podcast: DDW Editor Reece Armstrong looks into recent research which may explain why cancers can become more aggressive. Researchers in London and Milan may have discovered why cancers can become more aggressive without relying only on DNA mutations. A lot… Read More
Enhertu has been approved in the EU as the first HER2 directed therapy for patients with HER2 low metastatic breast cancer. The drug is approved as monotherapy for adult patients who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within six… Read More
Listen to this article on the DDW Podcast: DDW Editor Reece Armstrong explores recent research looking into why cancer cells are so effective at avoiding the body’s immune system. Scientists may have discovered clues to why cancer cells can avoid the body’s immune system in a study… Read More
Cancer cells can shrink or super-size themselves to survive drug treatment or other challenges within their environment, researchers have discovered. Scientists at The Institute of Cancer Research, London, combined biochemical profiling technologies with mathematical analyses to reveal how genetic changes lead to differences in the size of… Read More
Listen to this article on the DDW Podcast: DDW Editor Reece Armstrong covers news of a drug which could be used to treat triple-negative breast cancer with less side effects. A less toxic treatment for a specific type of breast cancer may be on the horizon due to… Read More
NICE has recommended Ninlaro (ixazomib) with lenalidomide and dexamethasone as an option relapsed or refractory multiple myeloma (RRMM) in adults who have received two or three lines of therapy. Since its launch in December 2017, ixazomib has been funded through the Cancer Drugs Fund and has been… Read More
Researchers have discovered a clinical drug that sensitises glioblastoma (GBM) cells to radiotherapy and could replace the current standard of care. Scientists from Korea and the US have unveiled the mechanism of radioresistance in GBM cells, identifying therapeutic targets to overcome radioresistance. GBM is a… Read More
This paid-for advertorial by Sphere Fluidics appeared in the SLAS 2023 Supplement, Volume 24 – Issue 1, Winter 2022/2023 Modern drug development has expanded from chemist-made substances to biologics and cell-based therapies. Despite the progress of the last two decades, we are only scratching the surface of what is possible and… Read More
